Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital

The interrelationship of smoking, CD4+ cell count, viral load and cancer in persons living with HIV

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Incidence of dyslipidemia in people with HIV who are treated with integrase inhibitors versus other antiretroviral agents

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Genome-wide association study of high-sensitivity C-reactive protein, D-dimer and Interleukin-6 levels in multi-ethnic HIV+ cohorts

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Influence of hepatitis C virus co-infection and hepatitis C virus treatment on risk of chronic kidney disease in HIV-positive persons

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

BACKGROUND: It is unknown if the carcinogenic effect of smoking is influenced by CD4 count and viral load (VL) in persons living with HIV.

MATERIAL AND METHODS: RESPOND participants with known smoking status were included. Poisson regression adjusting for baseline confounders investigated the interaction between current CD4/VL strata (good [CD4≥500/mm and VL<200 copies/mL], poor [CD4≤350/mm and VL>200 copies/ml] and intermediate [all other combinations]), smoking status and all cancers, non-AIDS defining cancers (NADC), smoking-related cancers (SRC), and infection-related cancers (IRC).

RESULTS: Of 19602 persons, 41.3% were never smokers 44.4% current and 14.4% previous smokers at baseline. CD4/VL strata were poor in 3.4%, intermediate in 44.8% and good in 51.8%. There were 513 incident cancers; incidence rate 6.9/1000 PYFU (95% CI 6.3-7.5). Current smokers had higher incidence of all cancer (adjusted incidence rate ratio 1.45; 1.17-1.79), NADC (1.65; 1.31-2.09), SRC (2.21; 1.53-3.20), and IRC (1.38; 0.97-1.96) vs never smokers. Those with poor CD4/VL had increased incidence of all cancer (5.36; 95% CI 3.71-7.75), NADC (3.14; 1.92-5.14), SRC (1.82; 0.76-4.41) and IRC (10.21; 6.06-17.20) versus those with good CD4/VL. There was no evidence that the association between smoking and cancer subtypes differed depending on the CD4/VL strata (p > 0.1, test for interaction).

CONCLUSIONS: In the large RESPOND consortium, the impact of smoking on cancer was clear and reducing smoking rates should remain a priority. The association between current immune deficiency, virological control and cancer was similar for never smokers, current smokers and previous smokers suggesting similar carcinogenic effects of smoking regardless of CD4 count and VL.

Original languageEnglish
Issue number5
Pages (from-to)747-757
Number of pages11
Publication statusPublished - 1 Apr 2021

ID: 61633662